Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MYOC | Q99972 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11876455 | 0.97 | KMT2A (0.58) | KMT2AMEN1ALDH1A1SMN1; SMN2NAMPT | |
| Nitric Acid SCHEMBL1719 | 0.82 | MAPK1 (0.62) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL11882305 | 0.80 | KMT2A (0.58) | KMT2AMEN1ALDH1A1SMN1; SMN2NAMPT | |
| SCHEMBL11878510 | 0.80 | KMT2A (0.58) | KMT2AMEN1ALDH1A1SMN1; SMN2NAMPT | |
| SCHEMBL11880307 | 0.80 | KMT2A (0.58) | KMT2AMEN1ALDH1A1SMN1; SMN2NAMPT | |
| SCHEMBL11878495 | 0.79 | ALDH1A1 (0.54) | KMT2AMEN1ALDH1A1SMN1; SMN2NAMPT | |
| SCHEMBL11877788 | 0.79 | KMT2A (0.53) | KMT2AMEN1ALDH1A1SMN1; SMN2NAMPT | |
| SCHEMBL16470336 | 0.79 | PLAU (0.64) | KMT2AMEN1NAMPTLMNANOS1 | |
| SCHEMBL3635716 | 0.78 | MAPK1 (0.64) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT | |
| Nitric Acid SCHEMBL3860512 | 0.78 | KMT2A (0.59) | KMT2AMEN1ALDH1A1SMN1; SMN2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595323-B2 | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | IL YANG PHARM. CO., LTD. (KR) | 2009-09-29 | — | — | US | disclosed |
| US-20040248918-A1 | Anticancer agents | IL YANG PHARM. CO., LTD. | 2004-12-09 | — | — | US | disclosed |
| WO-2004099187-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | IL YANG PHARM. CO. LTD. (KR) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004099186-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | IL YANG PHARM CO., LTD. (KR) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248918-A1 | Anticancer agents | BRDT, CHIA, RNASE1 | KMT2A 73/4885MEN1 2769/4885ALDH1A1 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.